It also reported retail investors were eager purchasers of Tesla (NASDAQ: TSLA ), Broadcom (NASDAQ: AVGO) and Apple (NASDAQ: ...

Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a ...

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Vanda (VNDA – Research Report) and keeping the price target at ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $18.0, a ...

Research analysts at StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) in a note issued to investors on Tuesday. The brokerage set a “hold” rating on ...

Vanda Pharmaceuticals Inc. (VNDA) stock saw a decline, ending the day at $4.35 which represents a decrease of $-0.16 or -3.55% from the prior close of $4.51. The stock opened at $4.51 and touched a ...

Vanda Pharmaceuticals (VNDA) provided an update on the tradipitant development program. Gastroparesis is a serious digestive disorder of the ...

A D.C. drugmaker is fighting the FDA on multiple fronts, from trying protect its intellectual property from generic ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant development program.

The Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) issued a ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a pharmaceutical company with a market capitalization of $256.56 million and impressive gross profit margins of 93.62%, disclosed through a social media post ...

Highlights faulty FDA review WASHINGTON, Jan. 27, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant ...